Thorne Announced as “Featured Speaker” at OneMedForum’s China Dinner Event

Share Article

OneMedForum convenes institutional investors and executives of healthcare and life science companies from around the world.

Christopher Thorne, Managing Partner of Broadline Capital

“The creation of an event such as this in New York to support innovative ideas and promising emerging companies is truly important to not only our region but the healthcare system globally,” Mayor Bloomberg said.

OneMedForum today announced that Christopher Thorne, the managing partner of Broadline Capital and chairman of EndoSphere Inc., is the “featured speaker” at OneMedForum NY 2011’s China dinner event. The forum convenes institutional investors and executives of healthcare and life science companies from around the world. This conference is the sixth OneMedForum, and second held in New York.

Recognizing the significance of the event, Mayor Michael Bloomberg proclaimed “OneMedForum Days” in New York City the week of the event.

“The creation of an event such as this in New York to support innovative ideas and promising emerging companies is truly important to not only our region but the healthcare system globally,” Bloomberg said.

Broadline Capital is a global private equity investment firm. A former management consultant at McKinsey & Company, Christopher Thorne became an early pioneer in China’s private equity industry when he formed Broadline Capital in 2005 to provide capital, expertise and management support to promising companies within China’s highly charged markets. Leading some of the most creative deals in its market categories, Broadline Capital received the private equity industry’s “Deal of the Year” award in Asia, named by Private Equity International for a 2007 China investment.

Thorne frequently provides strategic and governance oversight to Broadline Capital’s portfolio companies, including as chairman of EndoSphere Inc., a medical technology company that holds 23 U.S. and international issued and pending patents. EndoSphere develops and commercializes endoscopically implantable devices for the treatment of metabolic diseases including obesity and type 2 diabetes. The company completed an oversubscribed Series A Preferred Financing led by Broadline Capital in June 2011. Thorne previously founded and developed a software technology company that created efficiency gains for manufacturers, distributors and retailers in the trillion-dollar food and beverage, consumer packaged goods and retail supply chains. The resulting company managed more than $200 billion in transactions annually among industry trading partners that included more than 5,000 suppliers and 100,000 retail operators globally before the company sold to institutional investors at a nine-figure enterprise valuation in 2007.

Thorne received his Juris Doctor from Harvard Law School, Masters in Business Administration from Harvard Business School, and Bachelor of Arts degree (Magna Cum Laude) from Harvard University.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Bryan Kozlowski, Financial Controller
Visit website